Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …

With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying
patients who could benefit from these treatments becomes critical. In this study, we …

Amyloid and tau biomarkers for Alzheimer's disease are widely recognized diagnostic tools
for the identification of Alzheimer's disease pathology antemortem and are recommended by …

Background and Objectives β-amyloid (Aβ) staging models assume a single spatial-
temporal progression of amyloid accumulation. We assessed evidence for Aβ accumulation …

Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

Biological staging of individuals with Alzheimer's disease (AD) may improve diagnostic and
prognostic workup of dementia in clinical practice and the design of clinical trials. In this …

INTRODUCTION We studied how biomarkers of reactive astrogliosis mediate the
pathogenic cascade in the earliest Alzheimer's disease (AD) stages. METHODS We …

Studies over the last 100 years have suggested a link between inflammation, infectious
disease, and Alzheimer's Disease (AD). Understanding how the immune system changes …

White matter hyperintensities (WMHs) have a heterogeneous aetiology, associated with both
vascular risk factors and amyloidosis due to Alzheimer's disease. While spatial distribution of …

Background Amyloid-β (Aβ) accumulation is considered the earliest pathological change in
Alzheimer's disease (AD). The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) …